TrialJournal of Alzheimer's disease : JAD2026

Efficacy and safety of a novel, extended-release rivastigmine transdermal patch (TW-4752N) in patients with Alzheimer's disease: A 24-week randomized, double-blind trial with a 28-week open-label extension.

Yu Nakamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.